Roivant's rare disease shop captures FDA designations; China biotech lands $18M launch round
→ Weeks after Alexion’s $ALXN Rachelle Jacques jumped ship to assume the role of CEO of Enzyvant Sciences — forged out of Vivek Ramaswamy’s prolific shop at Roivant — the rare disease drugmaker’s preclinical enzyme replacement therapy for Farber disease, dubbed RVT-801, has won rare pediatric disease and fast track designations from the FDA.
→ The flow of cash into China’s biotech scene continues, with an $18 million launch round for neoantigen upstart GenoImmune. GF Xinde Investment Management led the round.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.